A Brief Introduction to Meningococcal Meningitis

Globally, six meningococcal serogroups (A, B, C, W135, X, and Y) have been identified for large-scale epidemics, with approximately 5 million people infected annually (according to WHO statistics);

The incidence rate of serogroup B meningococcal meningitis accounts for about 40% of the total;

Meningitis vaccines are part of China national first-class vaccine product series;

There is currently no serogroup B meningococcal meningitis vaccine in the China region, representing a significant unmet clinical need, and the market gap signifies a potential business opportunity.

Current Status of the Meningococcal Vaccine Market

International Market: GSK and Pfizer’s Group B meningococcal vaccines dominate the European and American markets;

Domestic Market: The meningococcal ACYW135 vaccines are relatively mature, with about 10 suppliers, but there is a temporary vacancy for Group B meningococcal vaccines;

Regional specificity of Group B meningococcal epidemic strains: The Group B meningococcal epidemic strains prevalent in Europe and America are different from those circulating in the China region, and the Group B meningococcal vaccines from Europe and America have not been approved in China.

Our Group B Meningococcal Vaccine Product

A fully independently developed “probiotic genetic engineering vaccine”;

The vaccine is composed of probiotics carrying foreign antigen fHBP protein A/B subfamily gene sequences;

Dual expression system of probiotics themselves + host cells, no vaccine adjuvant is needed;

Animal experimental data for the Group B meningococcal vaccine are as follows:

Preliminary determination results of the bactericidal efficiency of the antiserum against two fHBP target strains:

A subfamily selection ***** strain > 80

B subfamily selection ***** strain > 80

Market Competitive Advantages

Differentiated Competition: Be the first to capture the domestic Group B meningococcal vaccine market. It can also form a pentavalent vaccine with ACYW, creating an exclusive coverage of the meningococcal product market.

Safety and Vaccine Platform Flexibility: The probiotics are food-grade bacteria with negligible endotoxins, certified by the FDA as GRAS (Generally Recognized As Safe), and can be used to increase antigens as needed.

Manufacturing Process Cost (CMC): The overall production cost of the vaccine is significantly reduced. The probiotic amplification method is mature and simple, with a streamlined process and minimal equipment investment.

Provide GMP vaccine strains and related documentation;

The market size of meningococcal vaccines in China was 2.2 billion yuan in 2021, and it is expected to increase to 5.4 billion yuan by 2030.

Licensing Cooperation

Stage: Preclinical development completed

Provide vaccine samples free of charge, and potential partners designate third-party animal laboratories to conduct validation experiments and assess data

Assist partners in applying for clinical trials, participate in clinical design/evaluate data results

Attachments: List of completed documents

Preferred：Licensing

An upfront payment plus milestone payments and sales royalties. Share risks and benefits with partners

Optional: Investment

Investment by partner first, licensing after Phase I or Phase II clinical trials

Attachment: List of completed documents

Contact Us

If your company is interested in this opportunity, please contact the DrugTimes BD Team as soon as possible!

We will discuss the details with you. Thank you!

Email: BD@drugtimes.cn

Please indicate in the email subject line: Group B Meningococcal Vaccine

Many thanks!

【Editor’s note】The above content (~3100 words) is a quick translation of a Chinese article (posted on 2024-11-01) by DrugTimes team. To read the original article, please click here. All comments are warmly welcome. Many thanks!